SlideShare une entreprise Scribd logo
1  sur  32
Télécharger pour lire hors ligne
E M P OW E R I N G
PERSONALIZED
CANCER
T R E AT M E N T

CGIX
(NASDAQ)
Forward-Looking Statement
All statements pertaining to future financial and/or operating results, future growth in
research, technology, clinical development, and potential opportunities for Cancer
Genetics, Inc. (The Company) products and services, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited, to statements that
contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of potential products,
uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights and other risks discussed in
the Company’s registration statement on Form S-1 and other reports filed with the
Securities and Exchange Commission which is available for review at www.sec.gov.
Actual results may differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many uncertainties that
affect the Company's business.

The Company disclaims any intent or obligation to update these forward-looking
statements.

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

2
Growth-Stage, Oncology-Focused,
Personalized-Diagnostics Company
 Established multi-year track record of top-line growth with improving margins
 Hybrid business model providing proprietary genomic products, clinical
cancer testing and clinical trial services for biotechs and pharmas
 Portfolio of commercially available, IP-protected, revenue-creating products:
microarrays, DNA panels and probes

 47% revenue growth nine months 2013 over nine months 2012
 Experienced management team, active board of directors, and committed,
industry-leading scientific advisors
 Category continues to experience significant price-to-sales multiples and
premium acquisition valuations
 Established collaborations and partnerships with world-class institutions
including J.V. with Mayo Clinic: OncoSpire Genomics

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

3
Molecular Diagnostics are Changing our Understanding of
Cancer While Providing New Tools to Diagnose & Treat Patients
Our unique focus & approach supports the entire cancer care continuum

DIAGNOSIS

PROGNOSIS

THERANOSIS

Use genomics to
provide an accurate
and definitive typing
of the cancer

Assist in patient
outcome and disease
management

Personalize
therapeutic plan and
treatment options

Do I have cancer and
what type?

What are my survival
prospects?

What drug(s) to give,
how much, and when?

Proprietary Products

Focused Oncology Lab

Comprehensive Report

Integrated Molecular Diagnostic Testing Brings Benefits
Across the Entire Oncology Ecosystem
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

4
CGI’s Mission is to Personalize and Improve the
Success Rate in Cancer Treatment
Traditional Approach

Our Approach: Personalized Medicine

Phenotypic &
Physical Examination

Biomarkers and
Companion Diagnostics

Morphologic &
Pathological Analysis

Genomic Analysis &
Proprietary Algorithms

Large & Multiple
Specimens Required

Reduced Size and
Number of Specimens

Significant Delays to
Treatment

Improved Diagnoses &
Treatment Plans

25%

100%

Success Rate

Target Success Rate

Situation Today

Target For Tomorrow
Source: Clinical Trends in Molecular Medicine, Vol. 7, Issue 5

Integrating & Delivering Genomic Information About a Patient’s Cancer Can
Improve Care & Reduce Cost
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

5
Unique, Scalable and Multifaceted Business Model With A
Focus On Providing A Complete Solution
PROPRIETARY PRODUCTS

CLINICAL SERVICES

 Proprietary molecular
diagnostics & FISH probes

 Differentiated and complete
disease-focused solutions

 Biomarker and companion
diagnostic development

 Clinically validated

 Superior turnaround times

 IP-protected

 World-class expertise in
genomics and cytogenetics

 World-class genomics and
bioinformatics

 Sold globally

 Probe manufacturing
leverages low-cost, high
scale facility in India

BIOPHARMA PARTNERSHIPS

 Serving community
hospitals and labs through
unique Expand Dx™
program

 Drug-specific and cancerspecific assays
 Comprehensive focus in
hematologic and urogenital
cancers

Suite of Products and Services Provides Multiple Growth Drivers and Value to
Multiple Parties: Clinical Community, Biopharma & Medtech
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

6
Our Target Markets in Oncology Testing Comprise
Over 610,000 New Lives Annually in the U.S.
Hematological:

Urogenital:

Gynecological:

Lymphoma, Leukemia, M. Myeloma

Kidney, Bladder & Prostate

Cervical, Endometrial & Ovarian

149,990

376,310

84,140

2013 Estimated New Cases

2013 Estimated New Cases

2013 Estimated New Cases

(U.S.)

(U.S.)

(U.S.)

Death Rate
36%

Death Rate
16%

Death Rate
31%

Source: American Cancer Society

5 Products Launched in Target Segments
Over $6Bn in Annual U.S. Spend on Lab Testing In These Categories
Ability to Impact Over

610,000 New Lives Annually in the U.S.
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

7
5 Proprietary Diagnostic Products
Commercially Launched & In Market
Research &
Discovery

Clinical
Development

Commercial
Development

Launch &
Market Entry

Clinical Collaboration &
Validation Partners

MatBA® - Chronic & Small Lymphocytic Leukemia
MatBA® - Diffuse Large B-Cell Lymphoma
MatBA® - Mantle Cell Lymphoma
MatBA® - FL
MatBA® - MM

UroGenRA™ - Kidney
UroGenRA™ - Bladder
UroGenRA™-Prostate

FHACT™ - Cervical
FHACT™- Head&Neck
UGenRA™ - Cervical
UGenRA™ - Endometrial
UGenRA™ - Ovarian
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

8
Despite Improved Cancer Care, Case Numbers for
Hematologic Cancers are Still Rising
Identified Leukemia & Lymphoma Subtypes

Incidence & Survival Rates for NHLs
(US Only, per 100,000)

89

18.5

21.2
20.0 19.7 20.5

15.5
11.1

1

2

5

100

80

60

12

30

Number of Years Ago
Source: Genzyme & Nature

5.6

2

1975

12.6

6.2

7.1

7.9

1985

8.7

8.2

1995

6.9

7.3

2005

Incidence Rate

Survival Rate

Source: National Cancer Institute, National Center for Health
Statistics, SEER Dataset of Incidence & Mortality, FDA

Genomics-Based Tests like MatBA® are Critical and Improve
the Management and Cost of Hematologic Cancers
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

9
MatBA®-CLL/SLL Array-CGH Improves Risk
Stratification & Outcome Prediction
Impact on therapy selection &
clinical management of CLL
patients.

FISH
(Current Method)

(CGI Method)

█ Favorable

█ Intermediate

38% of cases in our study have
a favorable prognosis falling
under "watch & wait" approach.

38%

█ Unfavorable
█ Favorable/

85%

Intermediate
(no distinction)

39%
8% of cases with unfavorable
prognosis missed by FISH and
caught using MatBA®-CLL/SLL.

15%

23%

Genomic Aberrations Reported
by FISH:

Genomic Aberrations Reported
by MatBA®-CLL/SLL:

4

20

 Validated in Collaboration w/ Dr. Kanti Rai & Dr. Nicholas Chiorazzi (NSLIJ); 2 Datasets, 322 specimens
 Additional Validations being conducted w/ HUMC & Dana Farber; 2 Cohorts, 350+ specimens

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

10
MatBA® Can Group Patients Into Risk Groups and
Prognostication Classes




Being actively used in clinical care, in clinical trials
and in validation programs with Dana Farber,
MSKCC and HUMC
20 key genetic events/sites classify CLL patients
as having the potential for
Poor outcome = High risk
Intermediate outcome = Intermediate risk
Good outcome = Low risk

Time to First Treatment (TTFT)

Proportion Treatment-Free

MatBA®- CLL / SLL is a diagnostic tool and
prognostic indicator for patient stratification
and improved patient management

Detection of specific genomic imbalance in
CLL/SLL by MatBA®-CLL/SLL correlates
patient risk with time to first treatment
(TTFT) and shorter overall survival (OS)

 Patients classified as high risk had significantly
shorter overall survival (OS) times than those
classified as low or intermediate risk
 Provides additional risk stratification between low
and intermediate risk patients, not currently
available in other tests

–
–
–

P = 0.001
GOOD (n=74)
INTERMED (n=107)
POOR (n=47)

Time (months)

Overall Survival (OS)

Proportion Surviving

 Patients classified as high risk showed a shorter
time to first treatment (TTFT) compared to those
classified as low or intermediate risk

P = 0.090

P < 0.001
P = 0.010

–
–
–

GOOD (n=74)
INTERMED (n=107)
POOR (n=47)

Time (months)

Leukemia & Lymphoma – Houldsworth, et. al Sept. 18, 2013

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

11
UroGenRA™-Kidney Can Help Decide if Partial Kidney Removal
Is Required and Guide Treatment Selection
PROBLEM

SOLUTION

Men and women with renal masses
often undergo unnecessary
nephrectomy for accurate diagnosis
and experience delay in treatment

UroGenRA™ is designed to detect genomic
aberrations in a single assay in percutaneous
needle biopsies permitting accurate diagnosis
and reduction in cost & time to treatment

Development of diagnostic algorithm
 >600 RCC malignant subtypes (in-silico: SNP)
 >100 RCC malignant and benign subtypes (in-house: aCGH & FISH)
Prospective ongoing percutaneous needle biopsy (n>50) MSKCC
 Approaching 100% classification between benign and malignant lesions
 Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to surgical intervention
 J. Coleman (MSKCC)
Retrospective in-house FFPE validation (n>190) CCF
 Test to distinguish benign from malignant and specific malignant subtype
 E. Klein (Cleveland Clinic)

Clinical Benefits Include Reduction in Number of Highly Invasive Procedures,
Time to Treatment Selection and Time to Treatment Initiation
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

12
FHACT™ - A New Genomic Aid In The Screening &
Management Of Cervical Cancer
Cervical cancer effects nearly 500,000 women annually with nearly
80% in developing countries.

90% Regress
to Normal Grade
Decreased Risk for Cancer

•
•

HPV+
Abnormal
Cervical
Lesions

10% Progress
to Higher Grade
Increased Risk for Cancer

Provides critical information which reduces unnecessary and costly colposcopy
Predicts the progression and associated risk of cervical cancer progression

Genomic Amplification By Disease Category

Global Validation Partners
 National Cancer Institute
 Georgia Health Sciences Univ.
 University of Iowa
 Kamineni Hospital

Source: Luhn et al., IPV Poster, 2012
www.cmdrc.com

* - Launched Outside U.S. As A Product

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

13
IP Position and Detailed Global Strategy
Tool for Diagnosis and Prognosis of Mature B-Cell
Neoplasms
 US Issued Patent 8,580,713
 US Issued Patent 8,557,747
 Europe 10803548.6
 India 6657/DELNP/2012
 Canada 2,785,656
Methods of Analyzing Chromosomal Translocations
Using Fluorescence In Situ Hybridization (FISH)
 US Issued Patent 7,585,964
 US Issued Patent 7,964,345
 Canada 2,447,320

Panel for the Detection and Differentiation of Renal
Cortical Neoplasms
 US 11/932,422
 Europe 08844570.5
Methods for Detecting Human Papilloma VirusAssociated Cancers
 US 13/227,027
 US 13/474,111
 PCT/US2011/050681
Methods and Tools for the Diagnosis of Female
Gynecological Cancers and Precancers
 US 61/581,350

 Strong and growing portfolio in molecular-focused patents for disease
identification and stratification
 IP-based on unique algorithms across a broad group of chromosomal regions
 Validation of specific clinical endpoints that are associated with particular
disease outcomes or decisions
 Filing and maintenance of trademark portfolio

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

14
Large, Targeted Market Opportunities
 Commercialization Strategy

Target Markets


Collaborate to create and validate microarrays
and other proprietary products



Accelerate launch of large scale studies



Continue to growing sales force that calls on
hospitals and regional laboratories



Plan development of national footprint through
Expand Dx™



Leverage clinical infrastructure and proprietary
product portfolio for testing services that support
clinical trials



Expand sales emphasis of Select One™



Enhance distributor base in select emerging
economies



Partner with leading local cancer care providers
and hospitals to provide probes, arrays and
clinical services

Universities and Research Centers

Community Hospitals
Regional Cancer Centers
Oncologists and Pathologists

Biotechnology Companies
Pharmaceutical Companies

Emerging Markets

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

15
Unique Service Offering Developed to Enable Community
Hospitals to Improve Cancer Outcomes & Treat Patients Locally

Expanding & Developing Cancer Care
is a Top Priority for Hospital CEOs
& CFOs

4,000 to 5,000 Community Hospitals
& Laboratories in the U.S.

85% Of All U.S. Cancer Patients are
Initially Diagnosed in Community
Hospitals & Laboratories

$600,000 - $800,000 USD in Testing
Opportunity on Average per Hospital
Source: American Hospital Association

 Delivers better outcomes to
community hospitals and
laboratories
 Enables community hospitals
to bring “state-of-the-art”
genomic testing to patients

 Brings personalized medicine
to the community hospital vs.
just at academic and teaching
hospitals
 Allows community hospitals
to keep patients and treat
them locally
 Improving care and quality is
critical to maintaining
reimbursement for community
hospitals
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

16
Clinical Trial Services Showing Strong Growth
and Robust Pipeline

ONCOLOGY DRUGS ASSOCIATED
WITH BIOMARKER(S)

GROWTH IN CGI’s SELECT ONE™
CONTRACTS ($000)
$8,500

55%

21%

$2,700
$300

2011

2016

Source: Company Analysis and Management Estimates

2011

2012

2013

Approximate value of contracts with biotech and pharma clients

Well-Positioned for Use in Clinical Trials & Companion Diagnostic Programs

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

17
Gilead is Currently Using a Comprehensive Panel of CGI
Services & Proprietary Products in National & International
Trials for Hematologic Cancers

Highlights
 Comprehensive, biomarker-based patient profiling will help risk stratification and response
monitoring
 Improved patient profiling will result in improved trial efficacy for Gilead
 Testing will occur across several methodologies, including flow cytometry, FISH,
sequencing and mutation assays, and MatBA® microarrays

 CGI provides biomarker driven insight regarding patient targeting and potential outcomes
 Trials cover both national and international locations with all patient specimens being
processed in Rutherford, New Jersey

The Gilead Relationship Exemplifies the Significant Upside Potential of
CGI’s Select One™ Offering
CGIX Press Release: Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in Chronic Lymphocytic Leukemia

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

18
Collaborations with Premier Cancer Research Institutions
Leading Differentiated Research & Driving Product Adoption
Research Collaboration/
Licensing

Clinical
Services





Partnership
Highlights

 Kidney Cancer, DLBCL, MCL & FL



 Joint Venture Focused on Oncology
& Next Generation Sequencing



 Cervical Cancer



 DLBCL





 CLL





 Cervical Cancer & DLBCL



 Cervical Cancer



 Kidney Cancer





 DLBCL, Head & Neck Cancers





 CLL
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

19
Well-Positioned and Growing Internationally
Including in Emerging Economies
 International revenue comes from sale of oncology products
(DNA-FISH probes, arrays) and services to emerging economies
 Expect exposure to increase to emerging economies through
strong partnerships with Kamineni Life Sciences (India), Roche
(Central America & Caribbean), and DASA (Brasil)
 We focus our efforts through partnerships to ensure compliance
with local regulations and distribution issues
 Expanded distribution network with 4 new distributors covering 7
countries
 Continued focus on increasing international partnerships in 2013
and 2014

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

20
Roche Partnership
Expanding Market Presence Internationally
CGI provides genomic and biomarker testing services to 14
countries in Central America and the Caribbean.
Highlights
 CGI won a global RFP to help a strategic personalized medicine initiative for Roche
Servicios (Latin America)
 Roche sends all patient samples to the Rutherford facility where they are catalogued
and processed
 CGI interacts with both Roche and the hospital staff (pathologists, oncologists and
nurses) and supports delivery of reports through an online HIPAA compliant portal
 CGI and Roche recently expanded this relationship and will begin developing
workshops and training programs to drive adoption of biomarker-based cancer
diagnostics throughout Central America and the Caribbean
“By expanding our relationship, we are strengthening our ability to provide
patients the best service possible.”
Alvaro Soto, Roche Servicios, Central America & Caribbean General Manager
CGIX Press Release: Cancer Genetics, Inc. selected by Roche Servicios S.A. to provide services for the diagnosis and personalization of oncology treatment
CGIX Press Release: Cancer Genetics, Inc. expands relationship with Roche Servicios S.A.

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

21
Mayo Clinic Joint Venture
Investing in the Future – OncoSpire Genomics
Next Generation Sequencing in Oncology
Highlights
 JV, based in Rochester, MN, will develop clinical diagnostic products and services on NGS
platform(s) in areas of high clinical need

 Three initial projects in key oncology categories selected by the SRC (Scientific Review
Committee): Lung Cancer, Multiple Myeloma, Follicular Lymphoma
 CGI commits up to $6 M over initial three year period (2013 to 2015-16 expected)
 Mayo commits to “in-kind” services and support, use of facilities, NGS capabilities and
access to biorepository
 Joint Venture is exclusive in the project areas selected by CGI & Mayo
 Important company update and analyst day held November 22, 2013
The Value and Focus of Next Generation Sequencing is Moving from
Platforms to Clinically Relevant, Disease-Specific Applications
CGIX Press Release: Mayo Clinic Forms Joint Venture with Cancer Genetics

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

22
OncoSpire Genomics
Projects are Unique and Have High Value
Selected Projects Have Significant Clinical Value & May Yield Multiple Focused
Panels to Become the Standard of Care in NGS-Based Oncology Management

Informed
Discovery

Clinical
Development

1.6 million
new cases

Multiple Myeloma

20,920
new cases

Market Entry
(with partners)

Lung
Cancer

200,000
new cases

Commercial
Development

Follicular Lymphoma

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

23
Strong History of Growth
CGI Revenue & Clinical Volume Trends (2009 – 2013 thru 9 mos)
Total Revenue

Clinical Volume (Tests Processed)

($Mn)

$4.76
8,035

$4.30
6,610
$3.02
$2.52
3,622
3,146

$1.67
2,321

2009

2010

2011

2012

9 mos
2013

2009

2010

Trailing 12 Months Revenue is $5.8

2011

2012

9 mos
2013

Mn

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

24
Strong History of Growth - Revenue & Clinical Volume Trends
(Quarterly Comparison 2012 vs. 2013)
Total Revenue

Clinical Volume (Tests Processed)

($000)

$1,832

3,204

$1,705

2,920

37%

60%

97%
46%

$1,218

$1,243

$1,148

1,911

$835

2012
1st

Grants*

Grants*

2013

Quarter

2012
2nd

2013

Quarter

2012
3rd

1,704

1,623

1,610

Grants*

71%

19%

Grants*

2013

Quarter

2012

2013

1st Quarter

2012

2013

2nd Quarter

2012

2013

3rd Quarter

* Grants Q1,2012: $10K
Grants Q2,2012: $185K
Grants Q3, 2012: $280K
Grants Q3, 2013: $100K
2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

25
Summary Statement of Operations
(2009-2013 thru 9 mos)
Income Statement Item

2009

2010

2011

Revenue

$1,666

$2,522

$3,019

$4,302

$4,755

(866)

(995)

(98)

373

1,195

Gross Margin (%)

(52%)

(39%)

(3%)

9%

25%

Research & Development (R&D)

1,336

1,167

2,074

2,112

1,384

239

716

1,574

1,399

1,275

1,845

3,446

4,439

4,503

4,259

Operating Profit (Loss)

(4,286)

(6,323)

(8,185)

(7,641)

(5,723)

Net Income (Loss)

(7,328)

(8,407)

(19,887)

(6,666)

(9,848)

Gross Profit

Sales & Marketing (S&M)
General & Administrative (G&A)

2012 9 mos 2013

$ in thousands
2009 - 2012 audited

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

26
Summary Balance Sheet

Actual 09/30/13
Cash & Cash Equivalents
Stockholders’ Equity

Pro Forma (A)

$9,878

$52,129

4,882

47,133

$ in thousands
(A) Pro Forma basis gives effect to the receipt of net proceeds of approximately $42.3 MM from
the sale of 3,286,700 shares of common stock (including the underwriter’s over-allotment of
428,700 shares) at $14.00 per share, less offering expenses in our offering which closed on
October 28, 2013.

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

27
Consistent Focus on Gross Profit Improvements
Additional Efforts Focused Operationally in US & India

$ in Thousands

Gross Profit Margin

Highlights of Initiatives

800

25%

600

 Increased automation

400

 Process improvement and
innovation

9%
200
0

 Manufacturing in India (Probes)

(52%)

(39%)

(3%)
2011

(200)

(400)
(600)

9 mos
2013

 Capacity utilization
 Leveraging cloud for scale in IT,
data storage and clinical
operations
 Developing innovative model for
doing remote genetic analysis in
India

(800)

2009
(1,000)

2012

2010

2009-2012 audited

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

28
Multiple Customer Types Provide Diversified Revenue Mix
With Covered Lives Already in Place
Payor Revenue Mix 2013 (9 mos 2013)

Selected Payors

2%
13%
57 million covered lives through multiple payors:

9 mos
2013

26%

59%
Direct Bill Customer Types

Biotechs

Reimbursement Based

Academic
Cancer Facilities

Pharmas

Community &
Regional Labs

Direct Bill / Pay Based

Insurance & Probes

Companies, Hospitals
& Care Facilities

Medicare

Grants

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

29
Experienced and Focused Management and Boards
Board of Directors
Raju Chaganti, Ph.D.
Panna Sharma

| Keith Brownlie |
| Edmund Cannon |

John Pappajohn
Andrew Pecora, M.D.

Officers & Management Team
Raju Chaganti, Ph.D., FACMG Founder & Chairman
• 35 years in cancer research; 37 at MSKCC
• Major discoveries in cancer genomics
• Published 350+ articles, 4 patents

Panna Sharma President & CEO
• 15+ years as advisor to global life science & healthcare cos.
• Founded TSG Partners
• Chief Strategy Officer, iXL (IIXL)

Elizabeth Czerepak Chief Financial Officer
• 9 yrs as biotech VC; 18 yrs in pharma finance & deal making
• JPMorgan, Bear Stearns Health Innoventures, BASF, Roche,
Merck

Jane Houldsworth, Ph.D. Vice President of R&D
• 25 years in translational oncology research
• Published 50+ articles, 4 patents
• NIH grantee

| Franklyn Prendergast, M.D., Ph.D.
| The Honorable Tommy G. Thompson

Scientific Advisory Board
Andrea Califano, Ph.D.
Chairman of the Columbia Initiative for Systems Biology
Associate Director for Bioinformatics, Herbert Irving
Comprehensive Cancer Center

Timothy A. Chan, M.D., Ph.D.
Principal Investigator, Human Oncology and Pathogenesis
Program at Memorial Sloan-Kettering Cancer Center

Riccardo Dalla-Favera, M.D.
Director, Institute for Cancer Genetics at Columbia
University

Hans-Guido Wendel, M.D.
Principal Investigator, Cancer Genetics Laboratory at
Memorial Sloan-Kettering Cancer Center

Vundavalli V. Murty, Ph.D.
Director, Cancer Cytogenetic Laboratory and Molecular
Pathology at Columbia University

Andrew D. Zelenetz, M.D., Ph.D.
Chief of Lymphoma Service and Head of Molecular HemoOncology Laboratory, Department of Medicine at MSKCC

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

30
Strong, Commercially-Focused News Flow & Consistent
Achievement of Milestones Expected in Coming Quarters
Recent Accomplishments

Upcoming Milestones & Value Drivers



Accelerating market traction – Nearly
50% growth during 2013 over 2012

 Increasing covered lives market access through additional
payers and health care organizations



Launched UroGenRA™ – Kidney, a
unique microarray for kidney cancer
diagnosis and treatment selection in
collaboration with MSKCC

 Launching multi-marker NGS panel for leukemia and lymphomas
 Additional international agreements with life science tools
companies for DNA Probes and product distribution in key
geographies

Launched FHACT™ outside the U.S.
in collaboration with the National Cancer
Institute research publication

 UroGenRA™-Kidney – Next phase of data and results from
Cleveland Clinic collaboration



Received CLIA Approval for MatBA® –
MCL (Mantle Cell Lymphoma)

 MatBA® – Next phase of data and results from Dana Farber and
HUMC studies to help support value and reimbursement



Finalized Agreement with Multiplan
which gave us access to 57 million
covered lives

 FHACT™ - CE Approval, allows for IVDD use in E.U. & US launch
as a LDT under CLIA



Launched OncoSpire Genomics – A
Next Generation Sequencing Joint
Venture with Mayo Clinic



 Additional news on biopharma partners and relationships
 Announced initial set of projects (lung cancer, multiple myeloma
& follicular lymphoma) and development plan for OncoSpire
Genomics

2013 Cancer Genetics, Inc.

|

NASDAQ: CGIX

|

31
For further information, please contact us at ir@cancergenetics.com
Cancer Genetics, Inc.
Meadows Office Complex
201 Route 17 North
Rutherford, NJ 07070
(201) 528-9200
www.cancergenetics.com

Contenu connexe

Tendances

Exact Sciences 35th Annual J.P. Morgan Healthcare Conference Presentation
Exact Sciences 35th Annual J.P. Morgan Healthcare Conference PresentationExact Sciences 35th Annual J.P. Morgan Healthcare Conference Presentation
Exact Sciences 35th Annual J.P. Morgan Healthcare Conference PresentationExact Sciences
 
Investor & Analyst Day 2015: Cologuard Expansion (2/8)
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Investor & Analyst Day 2015: Cologuard Expansion (2/8)
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Exact Sciences
 
Group4_Week10_Final_Business_Plan_VERSION_8(1)
Group4_Week10_Final_Business_Plan_VERSION_8(1)Group4_Week10_Final_Business_Plan_VERSION_8(1)
Group4_Week10_Final_Business_Plan_VERSION_8(1)roxiefoxx
 
New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...
New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...
New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...Rafael Casiano
 
Exact Sciences Company Presentation Baird Healthcare Conference
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences Company Presentation Baird Healthcare Conference
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
 
Exact Sciences 2015 J.P Morgan Healthcare Conference Presentation
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences 2015 J.P Morgan Healthcare Conference Presentation
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
 
January 2017 Corporate Presentation
January 2017 Corporate PresentationJanuary 2017 Corporate Presentation
January 2017 Corporate Presentationoncolyticsinc
 
Complementary Tests and Companion Diagnostics in Oncology
Complementary Tests and Companion Diagnostics in OncologyComplementary Tests and Companion Diagnostics in Oncology
Complementary Tests and Companion Diagnostics in OncologyDr. Sima Salahshor
 
Exas october 2016 corporate presentation
Exas october 2016 corporate presentationExas october 2016 corporate presentation
Exas october 2016 corporate presentationExact Sciences
 
4 q17 corporate deck final web version
4 q17 corporate deck final web version4 q17 corporate deck final web version
4 q17 corporate deck final web versionExact Sciences
 
November 2016 corporate presentation final1
November 2016 corporate presentation   final1November 2016 corporate presentation   final1
November 2016 corporate presentation final1Exact Sciences
 
June 2016 Corporate Presentation
June 2016 Corporate PresentationJune 2016 Corporate Presentation
June 2016 Corporate PresentationSam Zastrow
 
Seventh Annual Next Generation Dx Summit
Seventh Annual Next Generation Dx SummitSeventh Annual Next Generation Dx Summit
Seventh Annual Next Generation Dx SummitJaime Hodges
 
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...Andrew Aijian
 
Jp morgan-2018-final-v3
Jp morgan-2018-final-v3Jp morgan-2018-final-v3
Jp morgan-2018-final-v3Exact Sciences
 
2016 J.P. Morgan Health Care Conference
2016 J.P. Morgan Health Care Conference2016 J.P. Morgan Health Care Conference
2016 J.P. Morgan Health Care ConferenceExact Sciences
 
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Andrew Aijian
 
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
 

Tendances (19)

Exact Sciences 35th Annual J.P. Morgan Healthcare Conference Presentation
Exact Sciences 35th Annual J.P. Morgan Healthcare Conference PresentationExact Sciences 35th Annual J.P. Morgan Healthcare Conference Presentation
Exact Sciences 35th Annual J.P. Morgan Healthcare Conference Presentation
 
Investor & Analyst Day 2015: Cologuard Expansion (2/8)
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Investor & Analyst Day 2015: Cologuard Expansion (2/8)
Investor & Analyst Day 2015: Cologuard Expansion (2/8)
 
Group4_Week10_Final_Business_Plan_VERSION_8(1)
Group4_Week10_Final_Business_Plan_VERSION_8(1)Group4_Week10_Final_Business_Plan_VERSION_8(1)
Group4_Week10_Final_Business_Plan_VERSION_8(1)
 
New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...
New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...
New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...
 
Exact Sciences Company Presentation Baird Healthcare Conference
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences Company Presentation Baird Healthcare Conference
Exact Sciences Company Presentation Baird Healthcare Conference
 
BIOC Presentation April 2014
BIOC Presentation April 2014BIOC Presentation April 2014
BIOC Presentation April 2014
 
Exact Sciences 2015 J.P Morgan Healthcare Conference Presentation
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences 2015 J.P Morgan Healthcare Conference Presentation
Exact Sciences 2015 J.P Morgan Healthcare Conference Presentation
 
January 2017 Corporate Presentation
January 2017 Corporate PresentationJanuary 2017 Corporate Presentation
January 2017 Corporate Presentation
 
Complementary Tests and Companion Diagnostics in Oncology
Complementary Tests and Companion Diagnostics in OncologyComplementary Tests and Companion Diagnostics in Oncology
Complementary Tests and Companion Diagnostics in Oncology
 
Exas october 2016 corporate presentation
Exas october 2016 corporate presentationExas october 2016 corporate presentation
Exas october 2016 corporate presentation
 
4 q17 corporate deck final web version
4 q17 corporate deck final web version4 q17 corporate deck final web version
4 q17 corporate deck final web version
 
November 2016 corporate presentation final1
November 2016 corporate presentation   final1November 2016 corporate presentation   final1
November 2016 corporate presentation final1
 
June 2016 Corporate Presentation
June 2016 Corporate PresentationJune 2016 Corporate Presentation
June 2016 Corporate Presentation
 
Seventh Annual Next Generation Dx Summit
Seventh Annual Next Generation Dx SummitSeventh Annual Next Generation Dx Summit
Seventh Annual Next Generation Dx Summit
 
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
 
Jp morgan-2018-final-v3
Jp morgan-2018-final-v3Jp morgan-2018-final-v3
Jp morgan-2018-final-v3
 
2016 J.P. Morgan Health Care Conference
2016 J.P. Morgan Health Care Conference2016 J.P. Morgan Health Care Conference
2016 J.P. Morgan Health Care Conference
 
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
 
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
 

En vedette (19)

Roil corporate presentation 11-26-13-reduced
Roil corporate presentation 11-26-13-reducedRoil corporate presentation 11-26-13-reduced
Roil corporate presentation 11-26-13-reduced
 
Mslp 6262013
Mslp 6262013Mslp 6262013
Mslp 6262013
 
14 nrt
14 nrt14 nrt
14 nrt
 
Pglc new york_102713
Pglc new york_102713Pglc new york_102713
Pglc new york_102713
 
Gnin 102013
Gnin 102013Gnin 102013
Gnin 102013
 
15 exeo
15 exeo15 exeo
15 exeo
 
Opxa 102013
Opxa 102013Opxa 102013
Opxa 102013
 
Kips 102013
Kips 102013Kips 102013
Kips 102013
 
Medl 102013
Medl 102013Medl 102013
Medl 102013
 
Roil 6262013
Roil 6262013Roil 6262013
Roil 6262013
 
Nrt jan2014 nrt ppt-email
Nrt jan2014 nrt ppt-emailNrt jan2014 nrt ppt-email
Nrt jan2014 nrt ppt-email
 
01 ltbr
01 ltbr01 ltbr
01 ltbr
 
13 roil
13 roil13 roil
13 roil
 
U sell investor-deck-reduced
U sell investor-deck-reducedU sell investor-deck-reduced
U sell investor-deck-reduced
 
03 icld
03 icld03 icld
03 icld
 
Qfor red chipjanconf
Qfor red chipjanconfQfor red chipjanconf
Qfor red chipjanconf
 
SSET Presentation
SSET PresentationSSET Presentation
SSET Presentation
 
Cgix profile 20131010
Cgix profile 20131010Cgix profile 20131010
Cgix profile 20131010
 
Smtp 102013
Smtp 102013Smtp 102013
Smtp 102013
 

Similaire à Cgix december investor-presentation

Interpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationInterpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationRedChip Companies, Inc.
 
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...European School of Oncology
 
Exact Sciences Corporate Presentation: June 2016
Exact Sciences Corporate Presentation: June 2016Exact Sciences Corporate Presentation: June 2016
Exact Sciences Corporate Presentation: June 2016Exact Sciences
 
2017 01 04 corporate presentation
2017 01 04 corporate presentation2017 01 04 corporate presentation
2017 01 04 corporate presentationKristine Mechem
 
Movers &amp; shakers interview with vivek trikha head diagnostics onc quest ...
Movers &amp; shakers interview with vivek trikha head  diagnostics onc quest ...Movers &amp; shakers interview with vivek trikha head  diagnostics onc quest ...
Movers &amp; shakers interview with vivek trikha head diagnostics onc quest ...oncquest
 
Exact Sciences Corporate Presentation: April 2016
Exact Sciences Corporate Presentation: April 2016Exact Sciences Corporate Presentation: April 2016
Exact Sciences Corporate Presentation: April 2016Exact Sciences
 
Life Raft Group: A New Model for Cancer Research
Life Raft Group: A New Model for Cancer ResearchLife Raft Group: A New Model for Cancer Research
Life Raft Group: A New Model for Cancer ResearchTRAIN Central Station
 
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...MedStatix, LLC
 
Jpm 2016-presentation-11416-final8 k
Jpm 2016-presentation-11416-final8 kJpm 2016-presentation-11416-final8 k
Jpm 2016-presentation-11416-final8 kExactir
 
Genetic Technologies Presentation - January 2021
Genetic Technologies Presentation -  January 2021Genetic Technologies Presentation -  January 2021
Genetic Technologies Presentation - January 2021RedChip Companies, Inc.
 
Genetic technologies Investor Presentation
Genetic technologies Investor PresentationGenetic technologies Investor Presentation
Genetic technologies Investor PresentationRedChip Companies, Inc.
 

Similaire à Cgix december investor-presentation (20)

GENE Presentation
GENE PresentationGENE Presentation
GENE Presentation
 
GENE Investor Deck May 2023
GENE Investor Deck May 2023GENE Investor Deck May 2023
GENE Investor Deck May 2023
 
Cancer Genetics Investor Deck
Cancer Genetics Investor DeckCancer Genetics Investor Deck
Cancer Genetics Investor Deck
 
Interpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationInterpace Diagnostics Investor Presentation
Interpace Diagnostics Investor Presentation
 
Gene Presentation October 2019
Gene Presentation October 2019Gene Presentation October 2019
Gene Presentation October 2019
 
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
 
Strand genomics features in CIO review
Strand genomics features in CIO reviewStrand genomics features in CIO review
Strand genomics features in CIO review
 
Exact Sciences Corporate Presentation: June 2016
Exact Sciences Corporate Presentation: June 2016Exact Sciences Corporate Presentation: June 2016
Exact Sciences Corporate Presentation: June 2016
 
CDx-NGS-webinar
CDx-NGS-webinarCDx-NGS-webinar
CDx-NGS-webinar
 
2017 01 04 corporate presentation
2017 01 04 corporate presentation2017 01 04 corporate presentation
2017 01 04 corporate presentation
 
Movers &amp; shakers interview with vivek trikha head diagnostics onc quest ...
Movers &amp; shakers interview with vivek trikha head  diagnostics onc quest ...Movers &amp; shakers interview with vivek trikha head  diagnostics onc quest ...
Movers &amp; shakers interview with vivek trikha head diagnostics onc quest ...
 
Exact Sciences Corporate Presentation: April 2016
Exact Sciences Corporate Presentation: April 2016Exact Sciences Corporate Presentation: April 2016
Exact Sciences Corporate Presentation: April 2016
 
Life Raft Group: A New Model for Cancer Research
Life Raft Group: A New Model for Cancer ResearchLife Raft Group: A New Model for Cancer Research
Life Raft Group: A New Model for Cancer Research
 
Investor Present 04202017
Investor Present  04202017Investor Present  04202017
Investor Present 04202017
 
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
 
Jpm 2016-presentation-11416-final8 k
Jpm 2016-presentation-11416-final8 kJpm 2016-presentation-11416-final8 k
Jpm 2016-presentation-11416-final8 k
 
16 bioc
16 bioc16 bioc
16 bioc
 
16 bioc
16 bioc16 bioc
16 bioc
 
Genetic Technologies Presentation - January 2021
Genetic Technologies Presentation -  January 2021Genetic Technologies Presentation -  January 2021
Genetic Technologies Presentation - January 2021
 
Genetic technologies Investor Presentation
Genetic technologies Investor PresentationGenetic technologies Investor Presentation
Genetic technologies Investor Presentation
 

Plus de RedChip Companies, Inc.

Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference  Small Stocks...Big North Graphite : Presenting at Global Online CEO Conference  Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
 
Btcs corporate presentation july 2014 final
Btcs corporate presentation  july 2014 finalBtcs corporate presentation  july 2014 final
Btcs corporate presentation july 2014 finalRedChip Companies, Inc.
 
Snwv corporate investor presentation - june 2014 - final
Snwv   corporate investor presentation - june 2014 - finalSnwv   corporate investor presentation - june 2014 - final
Snwv corporate investor presentation - june 2014 - finalRedChip Companies, Inc.
 
Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21RedChip Companies, Inc.
 
Intercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO ConferenceIntercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO ConferenceRedChip Companies, Inc.
 
Lightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO ConferenceLightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
Roil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO ConferenceRoil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
Neo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO ConferenceNeo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
American water works red_chip's global online ceo conference
American water works red_chip's global online ceo conferenceAmerican water works red_chip's global online ceo conference
American water works red_chip's global online ceo conferenceRedChip Companies, Inc.
 
Exeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO ConferenceExeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
Direct Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO ConferenceDirect Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
Lattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO ConferenceLattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 

Plus de RedChip Companies, Inc. (20)

Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference  Small Stocks...Big North Graphite : Presenting at Global Online CEO Conference  Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
 
The Coin Tree media kit deck
The Coin Tree   media kit deckThe Coin Tree   media kit deck
The Coin Tree media kit deck
 
StarStream Entertainment
StarStream EntertainmentStarStream Entertainment
StarStream Entertainment
 
StarStream Entertainment
StarStream EntertainmentStarStream Entertainment
StarStream Entertainment
 
StarStream Entertainment
StarStream EntertainmentStarStream Entertainment
StarStream Entertainment
 
Btcs corporate presentation july 2014 final
Btcs corporate presentation  july 2014 finalBtcs corporate presentation  july 2014 final
Btcs corporate presentation july 2014 final
 
Red chip preso 7 11-14
Red chip preso 7 11-14Red chip preso 7 11-14
Red chip preso 7 11-14
 
Snwv corporate investor presentation - june 2014 - final
Snwv   corporate investor presentation - june 2014 - finalSnwv   corporate investor presentation - june 2014 - final
Snwv corporate investor presentation - june 2014 - final
 
Gbi investor deck_12.04_revised
Gbi investor deck_12.04_revisedGbi investor deck_12.04_revised
Gbi investor deck_12.04_revised
 
Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21
 
DRNE INVESTOR PRESENTATION
DRNE INVESTOR PRESENTATIONDRNE INVESTOR PRESENTATION
DRNE INVESTOR PRESENTATION
 
Intercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO ConferenceIntercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO Conference
 
Atnm julyconference
Atnm julyconferenceAtnm julyconference
Atnm julyconference
 
Lightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO ConferenceLightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO Conference
 
Roil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO ConferenceRoil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO Conference
 
Neo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO ConferenceNeo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO Conference
 
American water works red_chip's global online ceo conference
American water works red_chip's global online ceo conferenceAmerican water works red_chip's global online ceo conference
American water works red_chip's global online ceo conference
 
Exeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO ConferenceExeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO Conference
 
Direct Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO ConferenceDirect Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO Conference
 
Lattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO ConferenceLattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO Conference
 

Dernier

Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 

Dernier (20)

Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 

Cgix december investor-presentation

  • 1. E M P OW E R I N G PERSONALIZED CANCER T R E AT M E N T CGIX (NASDAQ)
  • 2. Forward-Looking Statement All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Cancer Genetics, Inc. (The Company) products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited, to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company’s registration statement on Form S-1 and other reports filed with the Securities and Exchange Commission which is available for review at www.sec.gov. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. The Company disclaims any intent or obligation to update these forward-looking statements. 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 2
  • 3. Growth-Stage, Oncology-Focused, Personalized-Diagnostics Company  Established multi-year track record of top-line growth with improving margins  Hybrid business model providing proprietary genomic products, clinical cancer testing and clinical trial services for biotechs and pharmas  Portfolio of commercially available, IP-protected, revenue-creating products: microarrays, DNA panels and probes  47% revenue growth nine months 2013 over nine months 2012  Experienced management team, active board of directors, and committed, industry-leading scientific advisors  Category continues to experience significant price-to-sales multiples and premium acquisition valuations  Established collaborations and partnerships with world-class institutions including J.V. with Mayo Clinic: OncoSpire Genomics 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 3
  • 4. Molecular Diagnostics are Changing our Understanding of Cancer While Providing New Tools to Diagnose & Treat Patients Our unique focus & approach supports the entire cancer care continuum DIAGNOSIS PROGNOSIS THERANOSIS Use genomics to provide an accurate and definitive typing of the cancer Assist in patient outcome and disease management Personalize therapeutic plan and treatment options Do I have cancer and what type? What are my survival prospects? What drug(s) to give, how much, and when? Proprietary Products Focused Oncology Lab Comprehensive Report Integrated Molecular Diagnostic Testing Brings Benefits Across the Entire Oncology Ecosystem 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 4
  • 5. CGI’s Mission is to Personalize and Improve the Success Rate in Cancer Treatment Traditional Approach Our Approach: Personalized Medicine Phenotypic & Physical Examination Biomarkers and Companion Diagnostics Morphologic & Pathological Analysis Genomic Analysis & Proprietary Algorithms Large & Multiple Specimens Required Reduced Size and Number of Specimens Significant Delays to Treatment Improved Diagnoses & Treatment Plans 25% 100% Success Rate Target Success Rate Situation Today Target For Tomorrow Source: Clinical Trends in Molecular Medicine, Vol. 7, Issue 5 Integrating & Delivering Genomic Information About a Patient’s Cancer Can Improve Care & Reduce Cost 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 5
  • 6. Unique, Scalable and Multifaceted Business Model With A Focus On Providing A Complete Solution PROPRIETARY PRODUCTS CLINICAL SERVICES  Proprietary molecular diagnostics & FISH probes  Differentiated and complete disease-focused solutions  Biomarker and companion diagnostic development  Clinically validated  Superior turnaround times  IP-protected  World-class expertise in genomics and cytogenetics  World-class genomics and bioinformatics  Sold globally  Probe manufacturing leverages low-cost, high scale facility in India BIOPHARMA PARTNERSHIPS  Serving community hospitals and labs through unique Expand Dx™ program  Drug-specific and cancerspecific assays  Comprehensive focus in hematologic and urogenital cancers Suite of Products and Services Provides Multiple Growth Drivers and Value to Multiple Parties: Clinical Community, Biopharma & Medtech 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 6
  • 7. Our Target Markets in Oncology Testing Comprise Over 610,000 New Lives Annually in the U.S. Hematological: Urogenital: Gynecological: Lymphoma, Leukemia, M. Myeloma Kidney, Bladder & Prostate Cervical, Endometrial & Ovarian 149,990 376,310 84,140 2013 Estimated New Cases 2013 Estimated New Cases 2013 Estimated New Cases (U.S.) (U.S.) (U.S.) Death Rate 36% Death Rate 16% Death Rate 31% Source: American Cancer Society 5 Products Launched in Target Segments Over $6Bn in Annual U.S. Spend on Lab Testing In These Categories Ability to Impact Over 610,000 New Lives Annually in the U.S. 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 7
  • 8. 5 Proprietary Diagnostic Products Commercially Launched & In Market Research & Discovery Clinical Development Commercial Development Launch & Market Entry Clinical Collaboration & Validation Partners MatBA® - Chronic & Small Lymphocytic Leukemia MatBA® - Diffuse Large B-Cell Lymphoma MatBA® - Mantle Cell Lymphoma MatBA® - FL MatBA® - MM UroGenRA™ - Kidney UroGenRA™ - Bladder UroGenRA™-Prostate FHACT™ - Cervical FHACT™- Head&Neck UGenRA™ - Cervical UGenRA™ - Endometrial UGenRA™ - Ovarian 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 8
  • 9. Despite Improved Cancer Care, Case Numbers for Hematologic Cancers are Still Rising Identified Leukemia & Lymphoma Subtypes Incidence & Survival Rates for NHLs (US Only, per 100,000) 89 18.5 21.2 20.0 19.7 20.5 15.5 11.1 1 2 5 100 80 60 12 30 Number of Years Ago Source: Genzyme & Nature 5.6 2 1975 12.6 6.2 7.1 7.9 1985 8.7 8.2 1995 6.9 7.3 2005 Incidence Rate Survival Rate Source: National Cancer Institute, National Center for Health Statistics, SEER Dataset of Incidence & Mortality, FDA Genomics-Based Tests like MatBA® are Critical and Improve the Management and Cost of Hematologic Cancers 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 9
  • 10. MatBA®-CLL/SLL Array-CGH Improves Risk Stratification & Outcome Prediction Impact on therapy selection & clinical management of CLL patients. FISH (Current Method) (CGI Method) █ Favorable █ Intermediate 38% of cases in our study have a favorable prognosis falling under "watch & wait" approach. 38% █ Unfavorable █ Favorable/ 85% Intermediate (no distinction) 39% 8% of cases with unfavorable prognosis missed by FISH and caught using MatBA®-CLL/SLL. 15% 23% Genomic Aberrations Reported by FISH: Genomic Aberrations Reported by MatBA®-CLL/SLL: 4 20  Validated in Collaboration w/ Dr. Kanti Rai & Dr. Nicholas Chiorazzi (NSLIJ); 2 Datasets, 322 specimens  Additional Validations being conducted w/ HUMC & Dana Farber; 2 Cohorts, 350+ specimens 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 10
  • 11. MatBA® Can Group Patients Into Risk Groups and Prognostication Classes   Being actively used in clinical care, in clinical trials and in validation programs with Dana Farber, MSKCC and HUMC 20 key genetic events/sites classify CLL patients as having the potential for Poor outcome = High risk Intermediate outcome = Intermediate risk Good outcome = Low risk Time to First Treatment (TTFT) Proportion Treatment-Free MatBA®- CLL / SLL is a diagnostic tool and prognostic indicator for patient stratification and improved patient management Detection of specific genomic imbalance in CLL/SLL by MatBA®-CLL/SLL correlates patient risk with time to first treatment (TTFT) and shorter overall survival (OS)  Patients classified as high risk had significantly shorter overall survival (OS) times than those classified as low or intermediate risk  Provides additional risk stratification between low and intermediate risk patients, not currently available in other tests – – – P = 0.001 GOOD (n=74) INTERMED (n=107) POOR (n=47) Time (months) Overall Survival (OS) Proportion Surviving  Patients classified as high risk showed a shorter time to first treatment (TTFT) compared to those classified as low or intermediate risk P = 0.090 P < 0.001 P = 0.010 – – – GOOD (n=74) INTERMED (n=107) POOR (n=47) Time (months) Leukemia & Lymphoma – Houldsworth, et. al Sept. 18, 2013 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 11
  • 12. UroGenRA™-Kidney Can Help Decide if Partial Kidney Removal Is Required and Guide Treatment Selection PROBLEM SOLUTION Men and women with renal masses often undergo unnecessary nephrectomy for accurate diagnosis and experience delay in treatment UroGenRA™ is designed to detect genomic aberrations in a single assay in percutaneous needle biopsies permitting accurate diagnosis and reduction in cost & time to treatment Development of diagnostic algorithm  >600 RCC malignant subtypes (in-silico: SNP)  >100 RCC malignant and benign subtypes (in-house: aCGH & FISH) Prospective ongoing percutaneous needle biopsy (n>50) MSKCC  Approaching 100% classification between benign and malignant lesions  Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to surgical intervention  J. Coleman (MSKCC) Retrospective in-house FFPE validation (n>190) CCF  Test to distinguish benign from malignant and specific malignant subtype  E. Klein (Cleveland Clinic) Clinical Benefits Include Reduction in Number of Highly Invasive Procedures, Time to Treatment Selection and Time to Treatment Initiation 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 12
  • 13. FHACT™ - A New Genomic Aid In The Screening & Management Of Cervical Cancer Cervical cancer effects nearly 500,000 women annually with nearly 80% in developing countries. 90% Regress to Normal Grade Decreased Risk for Cancer • • HPV+ Abnormal Cervical Lesions 10% Progress to Higher Grade Increased Risk for Cancer Provides critical information which reduces unnecessary and costly colposcopy Predicts the progression and associated risk of cervical cancer progression Genomic Amplification By Disease Category Global Validation Partners  National Cancer Institute  Georgia Health Sciences Univ.  University of Iowa  Kamineni Hospital Source: Luhn et al., IPV Poster, 2012 www.cmdrc.com * - Launched Outside U.S. As A Product 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 13
  • 14. IP Position and Detailed Global Strategy Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms  US Issued Patent 8,580,713  US Issued Patent 8,557,747  Europe 10803548.6  India 6657/DELNP/2012  Canada 2,785,656 Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH)  US Issued Patent 7,585,964  US Issued Patent 7,964,345  Canada 2,447,320 Panel for the Detection and Differentiation of Renal Cortical Neoplasms  US 11/932,422  Europe 08844570.5 Methods for Detecting Human Papilloma VirusAssociated Cancers  US 13/227,027  US 13/474,111  PCT/US2011/050681 Methods and Tools for the Diagnosis of Female Gynecological Cancers and Precancers  US 61/581,350  Strong and growing portfolio in molecular-focused patents for disease identification and stratification  IP-based on unique algorithms across a broad group of chromosomal regions  Validation of specific clinical endpoints that are associated with particular disease outcomes or decisions  Filing and maintenance of trademark portfolio 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 14
  • 15. Large, Targeted Market Opportunities  Commercialization Strategy Target Markets  Collaborate to create and validate microarrays and other proprietary products  Accelerate launch of large scale studies  Continue to growing sales force that calls on hospitals and regional laboratories  Plan development of national footprint through Expand Dx™  Leverage clinical infrastructure and proprietary product portfolio for testing services that support clinical trials  Expand sales emphasis of Select One™  Enhance distributor base in select emerging economies  Partner with leading local cancer care providers and hospitals to provide probes, arrays and clinical services Universities and Research Centers Community Hospitals Regional Cancer Centers Oncologists and Pathologists Biotechnology Companies Pharmaceutical Companies Emerging Markets 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 15
  • 16. Unique Service Offering Developed to Enable Community Hospitals to Improve Cancer Outcomes & Treat Patients Locally Expanding & Developing Cancer Care is a Top Priority for Hospital CEOs & CFOs 4,000 to 5,000 Community Hospitals & Laboratories in the U.S. 85% Of All U.S. Cancer Patients are Initially Diagnosed in Community Hospitals & Laboratories $600,000 - $800,000 USD in Testing Opportunity on Average per Hospital Source: American Hospital Association  Delivers better outcomes to community hospitals and laboratories  Enables community hospitals to bring “state-of-the-art” genomic testing to patients  Brings personalized medicine to the community hospital vs. just at academic and teaching hospitals  Allows community hospitals to keep patients and treat them locally  Improving care and quality is critical to maintaining reimbursement for community hospitals 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 16
  • 17. Clinical Trial Services Showing Strong Growth and Robust Pipeline ONCOLOGY DRUGS ASSOCIATED WITH BIOMARKER(S) GROWTH IN CGI’s SELECT ONE™ CONTRACTS ($000) $8,500 55% 21% $2,700 $300 2011 2016 Source: Company Analysis and Management Estimates 2011 2012 2013 Approximate value of contracts with biotech and pharma clients Well-Positioned for Use in Clinical Trials & Companion Diagnostic Programs 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 17
  • 18. Gilead is Currently Using a Comprehensive Panel of CGI Services & Proprietary Products in National & International Trials for Hematologic Cancers Highlights  Comprehensive, biomarker-based patient profiling will help risk stratification and response monitoring  Improved patient profiling will result in improved trial efficacy for Gilead  Testing will occur across several methodologies, including flow cytometry, FISH, sequencing and mutation assays, and MatBA® microarrays  CGI provides biomarker driven insight regarding patient targeting and potential outcomes  Trials cover both national and international locations with all patient specimens being processed in Rutherford, New Jersey The Gilead Relationship Exemplifies the Significant Upside Potential of CGI’s Select One™ Offering CGIX Press Release: Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in Chronic Lymphocytic Leukemia 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 18
  • 19. Collaborations with Premier Cancer Research Institutions Leading Differentiated Research & Driving Product Adoption Research Collaboration/ Licensing Clinical Services   Partnership Highlights  Kidney Cancer, DLBCL, MCL & FL   Joint Venture Focused on Oncology & Next Generation Sequencing   Cervical Cancer   DLBCL    CLL    Cervical Cancer & DLBCL   Cervical Cancer   Kidney Cancer    DLBCL, Head & Neck Cancers    CLL 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 19
  • 20. Well-Positioned and Growing Internationally Including in Emerging Economies  International revenue comes from sale of oncology products (DNA-FISH probes, arrays) and services to emerging economies  Expect exposure to increase to emerging economies through strong partnerships with Kamineni Life Sciences (India), Roche (Central America & Caribbean), and DASA (Brasil)  We focus our efforts through partnerships to ensure compliance with local regulations and distribution issues  Expanded distribution network with 4 new distributors covering 7 countries  Continued focus on increasing international partnerships in 2013 and 2014 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 20
  • 21. Roche Partnership Expanding Market Presence Internationally CGI provides genomic and biomarker testing services to 14 countries in Central America and the Caribbean. Highlights  CGI won a global RFP to help a strategic personalized medicine initiative for Roche Servicios (Latin America)  Roche sends all patient samples to the Rutherford facility where they are catalogued and processed  CGI interacts with both Roche and the hospital staff (pathologists, oncologists and nurses) and supports delivery of reports through an online HIPAA compliant portal  CGI and Roche recently expanded this relationship and will begin developing workshops and training programs to drive adoption of biomarker-based cancer diagnostics throughout Central America and the Caribbean “By expanding our relationship, we are strengthening our ability to provide patients the best service possible.” Alvaro Soto, Roche Servicios, Central America & Caribbean General Manager CGIX Press Release: Cancer Genetics, Inc. selected by Roche Servicios S.A. to provide services for the diagnosis and personalization of oncology treatment CGIX Press Release: Cancer Genetics, Inc. expands relationship with Roche Servicios S.A. 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 21
  • 22. Mayo Clinic Joint Venture Investing in the Future – OncoSpire Genomics Next Generation Sequencing in Oncology Highlights  JV, based in Rochester, MN, will develop clinical diagnostic products and services on NGS platform(s) in areas of high clinical need  Three initial projects in key oncology categories selected by the SRC (Scientific Review Committee): Lung Cancer, Multiple Myeloma, Follicular Lymphoma  CGI commits up to $6 M over initial three year period (2013 to 2015-16 expected)  Mayo commits to “in-kind” services and support, use of facilities, NGS capabilities and access to biorepository  Joint Venture is exclusive in the project areas selected by CGI & Mayo  Important company update and analyst day held November 22, 2013 The Value and Focus of Next Generation Sequencing is Moving from Platforms to Clinically Relevant, Disease-Specific Applications CGIX Press Release: Mayo Clinic Forms Joint Venture with Cancer Genetics 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 22
  • 23. OncoSpire Genomics Projects are Unique and Have High Value Selected Projects Have Significant Clinical Value & May Yield Multiple Focused Panels to Become the Standard of Care in NGS-Based Oncology Management Informed Discovery Clinical Development 1.6 million new cases Multiple Myeloma 20,920 new cases Market Entry (with partners) Lung Cancer 200,000 new cases Commercial Development Follicular Lymphoma 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 23
  • 24. Strong History of Growth CGI Revenue & Clinical Volume Trends (2009 – 2013 thru 9 mos) Total Revenue Clinical Volume (Tests Processed) ($Mn) $4.76 8,035 $4.30 6,610 $3.02 $2.52 3,622 3,146 $1.67 2,321 2009 2010 2011 2012 9 mos 2013 2009 2010 Trailing 12 Months Revenue is $5.8 2011 2012 9 mos 2013 Mn 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 24
  • 25. Strong History of Growth - Revenue & Clinical Volume Trends (Quarterly Comparison 2012 vs. 2013) Total Revenue Clinical Volume (Tests Processed) ($000) $1,832 3,204 $1,705 2,920 37% 60% 97% 46% $1,218 $1,243 $1,148 1,911 $835 2012 1st Grants* Grants* 2013 Quarter 2012 2nd 2013 Quarter 2012 3rd 1,704 1,623 1,610 Grants* 71% 19% Grants* 2013 Quarter 2012 2013 1st Quarter 2012 2013 2nd Quarter 2012 2013 3rd Quarter * Grants Q1,2012: $10K Grants Q2,2012: $185K Grants Q3, 2012: $280K Grants Q3, 2013: $100K 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 25
  • 26. Summary Statement of Operations (2009-2013 thru 9 mos) Income Statement Item 2009 2010 2011 Revenue $1,666 $2,522 $3,019 $4,302 $4,755 (866) (995) (98) 373 1,195 Gross Margin (%) (52%) (39%) (3%) 9% 25% Research & Development (R&D) 1,336 1,167 2,074 2,112 1,384 239 716 1,574 1,399 1,275 1,845 3,446 4,439 4,503 4,259 Operating Profit (Loss) (4,286) (6,323) (8,185) (7,641) (5,723) Net Income (Loss) (7,328) (8,407) (19,887) (6,666) (9,848) Gross Profit Sales & Marketing (S&M) General & Administrative (G&A) 2012 9 mos 2013 $ in thousands 2009 - 2012 audited 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 26
  • 27. Summary Balance Sheet Actual 09/30/13 Cash & Cash Equivalents Stockholders’ Equity Pro Forma (A) $9,878 $52,129 4,882 47,133 $ in thousands (A) Pro Forma basis gives effect to the receipt of net proceeds of approximately $42.3 MM from the sale of 3,286,700 shares of common stock (including the underwriter’s over-allotment of 428,700 shares) at $14.00 per share, less offering expenses in our offering which closed on October 28, 2013. 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 27
  • 28. Consistent Focus on Gross Profit Improvements Additional Efforts Focused Operationally in US & India $ in Thousands Gross Profit Margin Highlights of Initiatives 800 25% 600  Increased automation 400  Process improvement and innovation 9% 200 0  Manufacturing in India (Probes) (52%) (39%) (3%) 2011 (200) (400) (600) 9 mos 2013  Capacity utilization  Leveraging cloud for scale in IT, data storage and clinical operations  Developing innovative model for doing remote genetic analysis in India (800) 2009 (1,000) 2012 2010 2009-2012 audited 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 28
  • 29. Multiple Customer Types Provide Diversified Revenue Mix With Covered Lives Already in Place Payor Revenue Mix 2013 (9 mos 2013) Selected Payors 2% 13% 57 million covered lives through multiple payors: 9 mos 2013 26% 59% Direct Bill Customer Types Biotechs Reimbursement Based Academic Cancer Facilities Pharmas Community & Regional Labs Direct Bill / Pay Based Insurance & Probes Companies, Hospitals & Care Facilities Medicare Grants 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 29
  • 30. Experienced and Focused Management and Boards Board of Directors Raju Chaganti, Ph.D. Panna Sharma | Keith Brownlie | | Edmund Cannon | John Pappajohn Andrew Pecora, M.D. Officers & Management Team Raju Chaganti, Ph.D., FACMG Founder & Chairman • 35 years in cancer research; 37 at MSKCC • Major discoveries in cancer genomics • Published 350+ articles, 4 patents Panna Sharma President & CEO • 15+ years as advisor to global life science & healthcare cos. • Founded TSG Partners • Chief Strategy Officer, iXL (IIXL) Elizabeth Czerepak Chief Financial Officer • 9 yrs as biotech VC; 18 yrs in pharma finance & deal making • JPMorgan, Bear Stearns Health Innoventures, BASF, Roche, Merck Jane Houldsworth, Ph.D. Vice President of R&D • 25 years in translational oncology research • Published 50+ articles, 4 patents • NIH grantee | Franklyn Prendergast, M.D., Ph.D. | The Honorable Tommy G. Thompson Scientific Advisory Board Andrea Califano, Ph.D. Chairman of the Columbia Initiative for Systems Biology Associate Director for Bioinformatics, Herbert Irving Comprehensive Cancer Center Timothy A. Chan, M.D., Ph.D. Principal Investigator, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center Riccardo Dalla-Favera, M.D. Director, Institute for Cancer Genetics at Columbia University Hans-Guido Wendel, M.D. Principal Investigator, Cancer Genetics Laboratory at Memorial Sloan-Kettering Cancer Center Vundavalli V. Murty, Ph.D. Director, Cancer Cytogenetic Laboratory and Molecular Pathology at Columbia University Andrew D. Zelenetz, M.D., Ph.D. Chief of Lymphoma Service and Head of Molecular HemoOncology Laboratory, Department of Medicine at MSKCC 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 30
  • 31. Strong, Commercially-Focused News Flow & Consistent Achievement of Milestones Expected in Coming Quarters Recent Accomplishments Upcoming Milestones & Value Drivers  Accelerating market traction – Nearly 50% growth during 2013 over 2012  Increasing covered lives market access through additional payers and health care organizations  Launched UroGenRA™ – Kidney, a unique microarray for kidney cancer diagnosis and treatment selection in collaboration with MSKCC  Launching multi-marker NGS panel for leukemia and lymphomas  Additional international agreements with life science tools companies for DNA Probes and product distribution in key geographies Launched FHACT™ outside the U.S. in collaboration with the National Cancer Institute research publication  UroGenRA™-Kidney – Next phase of data and results from Cleveland Clinic collaboration  Received CLIA Approval for MatBA® – MCL (Mantle Cell Lymphoma)  MatBA® – Next phase of data and results from Dana Farber and HUMC studies to help support value and reimbursement  Finalized Agreement with Multiplan which gave us access to 57 million covered lives  FHACT™ - CE Approval, allows for IVDD use in E.U. & US launch as a LDT under CLIA  Launched OncoSpire Genomics – A Next Generation Sequencing Joint Venture with Mayo Clinic   Additional news on biopharma partners and relationships  Announced initial set of projects (lung cancer, multiple myeloma & follicular lymphoma) and development plan for OncoSpire Genomics 2013 Cancer Genetics, Inc. | NASDAQ: CGIX | 31
  • 32. For further information, please contact us at ir@cancergenetics.com Cancer Genetics, Inc. Meadows Office Complex 201 Route 17 North Rutherford, NJ 07070 (201) 528-9200 www.cancergenetics.com